Phaseline

Companies › CytoCares

CytoCares: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CC312
anti-CD19 monoclonal antibody
CD19Phase 1Non-hodgkin Lymphoma; SLE - Systemic Lupus ErythematosusSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06037018CC312Phase 1Non-hodgkin LymphomaOncologyMar 2026
NCT07177911CC312Phase 1SLE - Systemic Lupus ErythematosusImmunologySep 2027

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.